AGEN

Agenus Inc. is a leading clinical-stage immuno-oncology company focused on discovering and developing innovative immunotherapy treatments aimed at enhancing the body’s immune response against cancer. Headquartered in Lexington, Massachusetts, Agenus is at the forefront of research in checkpoint inhibitors and other immunotherapies, positioning itself as a key player in the rapidly evolving oncology landscape. With a robust pipeline of therapeutics and a commitment to advancing patient care, Agenus is poised to capitalize on the increasing demand for effective cancer treatments globally.